{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:12:00Z","timestamp":1778836320588,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007365","name":"Fondazione IRCCS Policlinico San Matteo","doi-asserted-by":"publisher","award":["2020-12371760"],"award-info":[{"award-number":["2020-12371760"]}],"id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.esmoop.2022.100574","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T08:05:03Z","timestamp":1659686703000},"page":"100574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9611-1164","authenticated-orcid":false,"given":"A.","family":"Lasagna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bergami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lilleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Percivalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Quaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Comolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sarasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Sammartino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Arena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Secondino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cicognini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lo Cascio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Baldanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Cassaniti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.esmoop.2022.100574_bib3","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.39.2100822","article-title":"Nosocomial outbreak caused by the SARS-CoV-2 delta variant in a highly vaccinated population, Israel, July 2021","volume":"26","author":"Shitrit","year":"2021","journal-title":"Euro Surveill"},{"issue":"10317","key":"10.1016\/j.esmoop.2022.100574_bib4","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100574_bib5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2022.04.003","article-title":"Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron","volume":"40","author":"Mair","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2022.100574_bib6","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jmv.27697","article-title":"Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review","volume":"94","author":"Chenchula","year":"2022","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.esmoop.2022.100574_bib7","author":"Mbaeyi"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100574_bib8","article-title":"mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant","volume":"3","author":"Edara","year":"2022","journal-title":"Cell Rep Med"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100574_bib9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.esmoop.2022.100574_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100574_bib11","article-title":"COVID-19 vaccination in cancer patients: a narrative review","volume":"50","author":"Seneviratne","year":"2022","journal-title":"J\u00a0Int Med Res"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100574_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2021.10.014","article-title":"Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review","volume":"33","author":"Corti","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100574_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100574_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100458","article-title":"Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with cancer on active treatment: a prospective cohort study","volume":"7","author":"Lasagna","year":"2022","journal-title":"ESMO Open"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2022.100574_bib15","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"issue":"24","key":"10.1016\/j.esmoop.2022.100574_bib16","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.24.2001031","article-title":"Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020","volume":"25","author":"Percivalle","year":"2020","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100574_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100359","article-title":"Analysis of the humoral and cellular immune response after of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1\/PD-L1 inhibitors with or without chemotherapy: an update after six months of follow up","volume":"7","author":"Lasagna","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100574_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100272","article-title":"A\u00a0snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1\/PD-L1 inhibitors: a longitudinal cohort study","volume":"6","author":"Lasagna","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100574_bib19","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100574_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of covid-19 vaccination on transmission of alpha and delta variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100574_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100574_bib22","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.2174\/0929867329666220301113146","article-title":"COVID-19 effects on geriatric population and failures of aminoquinoline therapy: compilation of studies from EU, USA, and China; safety and efficacy of vaccines in the prevention & treatment of COVID-19","volume":"29","author":"Beeraka","year":"2022","journal-title":"Curr Med Chem"},{"issue":"10328","key":"10.1016\/j.esmoop.2022.100574_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(22)00147-7","article-title":"Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer","volume":"399","author":"Fendler","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100574_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jamaoncol.2022.0752","article-title":"Evaluation of the durability of the immune humoral response to COVID-19 vaccines in patients with cancer undergoing treatment or who received a stem cell transplant","volume":"8","author":"Khan","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100574_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3006","article-title":"Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients","author":"Chevallier","year":"2022","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100574_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2022.02.011","article-title":"Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination","volume":"40","author":"Ehmsen","year":"2022","journal-title":"Cancer Cell"},{"issue":"34","key":"10.1016\/j.esmoop.2022.100574_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4081","article-title":"Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection","volume":"7","author":"Yatim","year":"2021","journal-title":"Sci Adv"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100574_bib28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:48:50Z","timestamp":1778834930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2059702922002046"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100574","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100574"}}